Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06232551 · ClinicalTrials.gov registry record · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A NA study of Deep Vein Thrombosis and Venous Thromboembolic Disease, sponsored by Scott C. Woller, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 152,000
- Enrollment target
- 1
- Study location
NCT06232551 is a NA study of Deep Vein Thrombosis and Venous Thromboembolic Disease that is actively recruiting participants, run by Scott C. Woller, MD. The registered enrollment target is 152,000 participants, above the 1,598-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (9412% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06232551, a NA study of Deep Vein Thrombosis and Venous Thromboembolic Disease, is actively recruiting participants, sponsored by Scott C. Woller, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 152,000 participants
- Enrollment target
- 1
- Study location
Study Summary
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.
Conditions Studied
Interventions
- OTHER EHR (electronic health record) alert
- OTHER No EHR (electronic health record) alert
Study Locations (1)
Utah
- Intermountain Medical Center - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152,000 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06232551
The ClinicalTrials.gov registry entry for NCT06232551 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 152,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,598-participant average among 24 other Deep Vein Thrombosis trials with a reported enrollment target (9412% higher). The listed sponsor is Scott C. Woller, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Deep Vein Thrombosis appearing as the primary indexed condition, and to 2 interventions - of which EHR (electronic health record) alert is the first listed.
NCT06232551 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06232551 about?
NCT06232551 is a clinical study titled "Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism". A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is ...
What is the current status of trial NCT06232551?
This trial is currently recruiting. It is a NA study. The enrollment target is 152,000 participants. The study started on 2024-06-01. Estimated completion is 2025-09-30.
What conditions does trial NCT06232551 study?
This clinical trial studies the following conditions: Deep Vein Thrombosis, Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Hospitalism.
What interventions are being tested in trial NCT06232551?
The interventions under investigation include: EHR (electronic health record) alert (OTHER), No EHR (electronic health record) alert (OTHER).
Who is sponsoring clinical trial NCT06232551?
This trial is sponsored by Scott C. Woller, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06232551 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Deep Vein Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection
RECRUITING · NA
-
BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
ACTIVE NOT RECRUITING · NA
-
Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
ACTIVE NOT RECRUITING · NA
-
Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty
COMPLETED · NA
-
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.